Skip to main content
Have a personal or library account? Click to login
Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics Cover

Genetic polymorphisms in diabetes: Influence on therapy with oral antidiabetics

Acta Pharmaceutica
Volume 60 (2010): Issue 4 (December 2010)
By:  and    
Open Access
|Dec 2010
References

References

  1. M. Stumvoll, B. J. Goldstein and T. W. Haeften, Type 2 diabetes: principles of pathogenesis and therapy,(2005) 1333-1346; DOI: 10.1016/S0140-6736(05)61032-X.
    Open DOISearch in Google Scholar
  2. M. Małecki and J. Skupień, Problems in differential diagnosis of diabetes types,(2008) 435-440.
    Search in Google Scholar
  3. K. Almind, A. Doria and C. R. Kahn, Putting the genes for type 2 diabetes on the map,(2001) 277-279; DOI: 10.1038/85405.
    Open DOISearch in Google Scholar
  4. M. N. Weedon, M. I. McCarthy, G. Hitman, M. Walker, C. J. Groves, E. Zeggini, N. W. Rayner, B. Shields, K. R. Owen, A. T. Hattersley and T. M. Frayling, Combining information from common type 2 diabetes risk polymorphisms improves disease prediction,(2006) e374; DOI: 10.1371/journal.pmed.0030374.
    Open DOISearch in Google Scholar
  5. R. Murphy, S. Ellard and A. T. Hattersley, Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes,(2008) 200-213; DOI: 10.1038/ncpendmet0778.
    Open DOISearch in Google Scholar
  6. O. Nyunt, J. Y. Wu, I. N. McGown, M. Harris, T. Huynh, G. M. Leong, D. M. Cowley and A. M. Cotterill, Investigating maturity onset diabetes of the young,(2009) 67-74.
    Search in Google Scholar
  7. C. Rongrong, H. Khalid and A. A. Maryam, Neonatal and late-onset diabetes mellitus caused by failure of pancreatic development: report of 4 more cases and a review of the literature.(2008) 1541-1547; DOI: 10.1542/peds.2007-3543.
    Open DOISearch in Google Scholar
  8. L. Aguilar-Bryan and J. Bryan, Neonatal diabetes mellitus,(2008) 265-291; DOI: 10.1210/er.2007-0029.
    Open DOISearch in Google Scholar
  9. M. Polak and H. Cavé, Neonatal diabetes mellitus: a disease linked to multiple mechanisms,(2007) 12; DOI: 10.1186/1750-1172-2-12.
    Open DOISearch in Google Scholar
  10. W. E. Evans and H. L. McLeod, Pharmacogenomics - drug disposition, drug targets and side effects,(2003) 538-549; DOI: 10.1056/NEJMra020526.
    Open DOISearch in Google Scholar
  11. R. Weinshilboum, Inheritance and drug response,(2003) 529-537; DOI: 10.1056/NEJMra020021.
    Open DOISearch in Google Scholar
  12. W. E. Evans and M. V. Relling, Pharmacogenomics: translating functional genomics into rational therapeutics,(1999) 487-491; DOI: 10.1126/science.286.5439.487.
    Open DOISearch in Google Scholar
  13. Y. Nakamura, Pharmacogenomics and drug toxicity,(2008) 856-858; DOI: 10.1056/NEJMe0805136.
    Open DOISearch in Google Scholar
  14. R. A. Wilke, D. W. Lin, D. M. Roden, P. B. Watkins, D. Flockhart, I. Zineh, K. M. Giacomini and R. M. Krauss, Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges,(2007) 904-916; DOI: 10.1038/nrd2423.
    Open DOISearch in Google Scholar
  15. N. Azarpira and M. H. Aghdaie, Frequency of C3435 MDR1 and A6896G CYP3A5 single nucleotide polymorphism in an Iranian population and comparison with other ethnic groups,(2006) 131-136.
    Search in Google Scholar
  16. J. L. Evans and R. J. Rushakoff, Oral Pharmacological Agents for Type 2 Diabetes: Oral Agents, Incretions and other »Non-Insulin« Pharmacologic Interventions for Diabetes,(Eds. I. D. Goldfine and R. J. Rushakoff) last author version May 2010;
    Search in Google Scholar
  17. B. Vrhovac, I. Aganović, B. Anić, V. Barbarić Babić, I. Bakran, I. Barić, B. Baršić, J. Begovac, A. Beus, M. Bilušić, V. Bradamante, B. Srećko, B. Buljević, D. Čvorišćec, V. Degoricija, V. Dorn, Z. Duraković, V. Erdeljić, I. Francetić, V. Gašparović, I. Gjenero Margan, M. Herceg, M. Huić, V. Ivančan, D. Ivanović, T. Jukić, S. Kalenić, R. Katalinić, M. Katić, P. Kes, I. Klinar, M. Koršić, Ž. Krznarić, S. Lovasić, A. Lovrenčić Huzjan, M. Lovrenčić, D. Macan, V. Macolić Šarinić, K. Makar-Aušperger, I. Merćep, Ž. Metelko, S. Ostojić Kolonić, J. Pasini, I. Radman, Ž. Reiner, D. Rogić, M. Skerlev, E. Verona-Krznar, H. Vrčić, R. Vrhovac, I. Vukušić and S. Zupančić-Šalek,, 4ed., Medicinska naklada, Zagreb 2003, pp. 89-93.
    Search in Google Scholar
  18. N. Mulabegović, S. Lučić, S. Loga Zec, S. Čustović and F. Bečić,, Federalno ministarstvo zdravstva: Udruženje farmakologa Federacije Bosne i Hercegovine, Sarajevo 2009, pp. 106-117.
    Search in Google Scholar
  19. R. K. Campbell, Type 2 diabetes: where we are today: An overview of disease burden, current treatments, and treatment strategies,(Suppl 1) (2009) S3-S9; DOI: 10.1331/JAPhA.2009.09077.
    Open DOISearch in Google Scholar
  20. M. L. Reitman and E. E. Schadt, Pharmacogenetics of metformin response: a step in the path toward personalized medicine,(2007) 1226-1229; DOI: 10.1172/JCI32133.
    Open DOISearch in Google Scholar
  21. M. I. McCarthy and A. T. Hattersley, Learning from molecular genetics. Novel insights arising from the definition of genes for monogenic and type 2 diabetes,(2008) 2889-2898; DOI: 10.2337/db08-0343.
    Open DOISearch in Google Scholar
  22. A. T. Hattersley, Unlocking the secrets of the pancreatic β cell: man and mouse provide the key,(2004) 314-316; DOI: 10.1172/JCI200422506.
    Open DOISearch in Google Scholar
  23. A. T. Hattersley and E. R. Pearson, Minireview: Pharmacogenetics and beyond: The interaction of therapeutic response, β-cell physiology, and genetics in diabetes,(2006) 2657-2663; DOI: 10.1210/en.2006-0152.
    Open DOISearch in Google Scholar
  24. R. Khalil, F. Al-Sheyab, E. Khamaiseh, M. A. Halaweh and H. A. Abder-Rahman, Screening of mutations in the GCK gene in Jordanian maturity-onset diabetes of the young type 2 (MODY2) patients,(2009) 500-506; DOI: 10.4238/vol8-2gmr597.
    Open DOISearch in Google Scholar
  25. N. Tinto, A. Zagari, M. Capuano, A. De Simone, V. Capobianco, G. Daniele, M. Giugliano, R. Spadaro, A. Franzese and L. Sacchetti, Glucokinase gene mutations: Structural and genotype-phenotype analyses in MODY children from south Italy,(2008) 1870; DOI: 10.1371/journal.pone.0001870.
    Open DOISearch in Google Scholar
  26. P. Froguel, H. Zouali, N. Vionnet, G. Velho, M. Vaxillaire, F. Sun, S. Lesage, M. Stoffel, J. Takeda, P. Passa, M. A. Permutt, J. S. Beckmann, G. I. Bell and D. Cohen, Familial hyperglycemia due to mutations in glucokinase - definition of a subtype of diabetes mellitus,(1993) 697-702; DOI: 10.1056/NEJM199303113281005.
    Open DOISearch in Google Scholar
  27. E. R. Pearson, G. Velho, P. Clark, A. Stride, M. Shepherd, T. M. Frayling, M. P. Bulman, S. Ellard, P. Froguel and A. T. Hattersley, β-Cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1α and glucokinase mutations,(2001) S101-S107; DOI: 10.2337/diabetes.50.2007.S101.
    Open DOISearch in Google Scholar
  28. A. Stride, S. Ellard, P. Clark, L. Shakespeare, M. Salzmann, M. Shepherd and A. T. Hattersley, β-Cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1α mutation carriers,(2005) 1751-1756; DOI: 10.2337/diacare.28.7.1751.
    Open DOISearch in Google Scholar
  29. T. M. Frayling, J. C. Evans, M. P. Bulman, E. Pearson, L. Allen, K. Owen, C. Bingham, M. Hannemann, M. Shepherd, S. Ellard and A. T. Hattersley, β-Cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors,(2001) S94-S100; DOI: 10.2337/diabetes.50.2007.S94.
    Open DOISearch in Google Scholar
  30. I. D. Dukes, S. Sreenan, M. W. Roe, M. Levisetti, Y. P. Zhou, D. Ostrega, G. I. Bell, M. Pontoglio, M. Yaniv, L. Philipson and K. S. Polonsky, Defective pancreatic β-cell glycolytic signaling in hepatocyte nuclear factor-1α-deficient mice,(1998) 24457-24464; DOI: 10.1074/jbc.273.38.24457.
    Open DOISearch in Google Scholar
  31. H. Wang, P. A. Antinozzi, K. A. Hagenfeldt, P. Maechler and C. B. Wollheim, Molecular targets of a human HNF1α mutation responsible for pancreatic β-cell dysfunction,(2000) 4257-4264; DOI: 10.1093/emboj/19.16.4257.
    Open DOISearch in Google Scholar
  32. E. R. Pearson, W. G. Liddell, M. Shepherd, R. J. Corrall and A. T. Hattersley, Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor 1α gene mutations: evidence for pharmacogenetics in diabetes,(2000) 543-545; DOI: 10.1046/j.1464-5491.2000.00305.x.
    Open DOISearch in Google Scholar
  33. E. R. Pearson, B. J. Starkey, R. J. Powell, F. M. Gribble, P. M. Clark and A. T. Hattersley, Genetic cause of hyperglycaemia and response to treatment in diabetes,(2003) 1275-1281; DOI: 10.1016/S0140-6736(03)14571-0.
    Open DOISearch in Google Scholar
  34. P. Boileau, C. Wolfrum, D. Q. Shih, T. A. Yang, A. W. Wolkoff and M. Stoffel1, Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1α-deficient mice. A mechanism for hypersensitivity to sulfonylurea therapy in patients with Maturity-Onset Diabetes of the Young, Type 3 (MODY3),(2002) 343-348; DOI: 10.2337/diabetes.51.2007.S343.
    Open DOISearch in Google Scholar
  35. E. H. Hathout, B. N. Cockburn, J. W. Mace, J. Sharkney, J. Chen-Daniel and G. I. Bell, A case of hepatocyte nuclear factor-1α diabetes/MODY 3 masquerading as type 1 diabetes in a Mexican-American adolescent and responsive to a low dose of sulphonylurea (letter),(1999) 867-868; DOI: 10.2337/diacare.22.5.867.
    Open DOISearch in Google Scholar
  36. A. P. Lambert, S. Ellard, L. I. Allen, I. W. Gallen, K. M. Gillespie, P. Bingley and A. T. Hattersley, Identifying hepatic nuclear factor 1α mutations in children and young adults with a clinical diagnosis of type 1 diabetes,(2003) 333-337; DOI: 10.2337/diacare.26.2.333.
    Open DOISearch in Google Scholar
  37. M. Shepherd, E. R. Pearson, J. Houghton, G. Salt, S. Ellard and A. T. Hattersley, No deterioration in glycemic control in HNF-1α maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas,(2003) 3191-3192; DOI: 10.2337/diacare.26.11.3191-a.
    Open DOISearch in Google Scholar
  38. T. H. Lindner, P. R. Njolstad, Y. Horikawa, L. Bostad, G. I. Bell and O. Sovik, A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1β,(1999) 2001-2008; DOI: 10.1093/hmg/8.11.2001.
    Open DOISearch in Google Scholar
  39. E. R. Pearson, M. K. Badman, C. R. Lockwood, P. M. Clark, S. Ellard, C. Bingham and A. T. Hattersley, Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1α and -1β mutations,(2004) 1102-1107; DOI: 10.2337/diacare.27.5.1102.
    Open DOISearch in Google Scholar
  40. M. A. Maestro, S. F. Boj, R. F. Luco, C. E. Pierreux, J. Cabedo, J. M. Servitja, M. S. German, G. G. Rousseau, F. P. Lemaigre and J. Ferrer, Hnf6 and Tcf2 (MODY5) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas,(2003) 3307-3314; DOI: 10.1093/hmg/ddg355.
    Open DOISearch in Google Scholar
  41. R. Masia, J. C. Koster, S. Tumini, F. Chiarelli, C. Colombo, C. G. Nichols and F. Barbetti, An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes,(2007) 328-336; DOI: 10.2337/db06-1275.
    Open DOISearch in Google Scholar
  42. M. A. Sperling, ATP-sensitive potassium channels - neonatal diabetes mellitus and beyond,(2006) 507-510; DOI: 10.1056/NEJMe068142.
    Open DOISearch in Google Scholar
  43. D. Enkvetchakul and C. G. Nichols, Gating mechanism of KATP channels: function fits form,(2003) 471-480; DOI: 10.1085/jgp.200308878.
    Open DOISearch in Google Scholar
  44. P. Proks, J. F. Antcliff, J. Lippiat, A. L. Gloyn, A. T. Hattersley and F. M. Ashcroft, Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features,(2004) 17539-17544; DOI: 10.1073/pnas.0404756101.
    Open DOISearch in Google Scholar
  45. E. R. Pearson, I. Flechtner, P. R. Njølstad, M. T. Malecki, S. E. Flanagan, B. Larkin, F. M. Ashcroft, I. Klimes, E. Codner, V. Iotova, A. S. Slingerland, J. Shield, J. J. Robert, J. J. Holst, P. M. Clark, S. Ellard, O. Søvik, M. Polak and A. T. Hattersley, Neonatal diabetes international collaborative group, Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations,(2006) 467-477; DOI: 10.1056/NEJMoa061759.
    Open DOISearch in Google Scholar
  46. J. C. Koster, M. S. Remedi, C. Dao and C. G. Nichols, ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy,(2005) 2645-2654; DOI: 10.2337/diabetes.54.9.2645.
    Open DOISearch in Google Scholar
  47. A. P. Babenko, M. Polak, H. Cavé, K. Busiah, P. Czernichow, R. Scharfmann, J. Bryan, L. Aguilar-Bryan, M. Vaxillaire and P. Froguel, Activating mutations in the ABCC8 gene in neonatal diabetes mellitus,(2006) 456-466; DOI: 10.1056/NEJMoa055068.
    Open DOISearch in Google Scholar
  48. M. Rafiq, S. E. Flanagan, A. M. Patch, B. M. Shields, S. Ellard and A. T. Hattersley, The Neonatal diabetes international collaborative group, Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations,(2008) 204-209; DOI: 10.2337/dc07-1785.
    Open DOISearch in Google Scholar
  49. A. Zung, B. Glaser, R. Nimri and Z. Zadik, Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2,(2004) 5504-5507; DOI: 10.1210/jc.2004-1241.
    Open DOISearch in Google Scholar
  50. M. S. Remedi and C. G. Nichols, Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic β-cells,(2008) e206; DOI: 10.1371/journal.pmed.0050206.
    Open DOISearch in Google Scholar
  51. G. Sesti, E. Laratta, M. Cardellini, F. Andreozzi, S. Del Guerra, C. Irace, A. Gnasso, M. Grupillo, R. Lauro, M. L. Hribal, F. Perticone and P. Marchetti, The E23K variant ofencoding the pancreatic β-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes,(2006) 2334-2339; DOI: 10.1210/jc.2005-2323.
    Open DOISearch in Google Scholar
  52. J. Kirchheiner, I. Roots, M. Goldammer, B. Rosenkranz and J. Brockmöller, Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance,(2005) 1209-1225; DOI: 10.2165/00003088-200544120-00002.
    Open DOISearch in Google Scholar
  53. A. Holstein, A. Plaschke, M. Ptak, E. H. Egberts, J. El-Din, J. Brockmöller and J. Kirchheiner, Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents,(2005) 103-106; DOI: 10.1111/j.1365-2125.2005.02379.x.
    Open DOISearch in Google Scholar
  54. J. Kirchheiner, J. Brockmöller, I. Meineke, S. Bauer, W. Rohde, C. Meisel and I. Roots, Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers,(2002) 286-296; DOI: 10.1067/mcp.2002.122476.
    Open DOISearch in Google Scholar
  55. J. Kirchheiner, S. Bauer, I. Meineke, W. Rohde, V. Prang, C. Meisel, I. Roots and J. Brockmöller, Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers,(2002) 101-109; DOI: 10.1067/mcp.2002.122476.
    Open DOISearch in Google Scholar
  56. J. Kirchheiner, I. Meineke, G. Müller, S. Bauer, W. Rohde, C. Meisel, I. Roots and J. Brockmöller, Influence of CYP2C9 and CYP2D6 polymorphisms on pharmacokinetics of nateglinide in genotyped healthy volunteers,(2004) 267-278; DOI: 10.2165/00003088-200443040-00005.
    Open DOISearch in Google Scholar
  57. Q. Huang, J. Y. Yin, X. P. Dai, Q. Pei, M. Dong, Z. G. Zhou, X. Huang, M. Yu, H. H. Zhou and Z. Q. Liu, IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population,(2010) 709-717; DOI: 10.1038/aps.2010.47.
    Open DOISearch in Google Scholar
  58. O. Bozkurt, A. de Boer, D. E. Grobbee, E. R. Heerdink, H. Burger and O. H. Klungel, Pharmacogenetics of glucose-lowering drug treatment: a systematic review,(2007) 291-302.
    Open DOISearch in Google Scholar
  59. Y. Shu, S. A. Sheardown, C. Brown, R. P. Owen, S. Zhang, R. A. Castro, A. G. Ianculescu, L. Yue, J. C. Lo, E. G. Burchard, C. M. Brett and K. M. Giacomini, Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action,(2007) 1422-1431; DOI: 10.1172/JCI30558.
    Open DOISearch in Google Scholar
  60. D. S. Wang, J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinke and Y. Sugiyama, Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin,(2002) 510-515; DOI: 10.1124/jpet.102.034140.
    Open DOISearch in Google Scholar
  61. N. Kimura, S. Masuda, Y. Tanihara, H. Ueo, M. Okuda, T. Katsura and K. Inui, Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1, Drug Metab.(2005) 379-386; DOI: 10.2133/dmpk.20.379.
    Open DOISearch in Google Scholar
  62. E. R. Pearson, L. A. Donnelly, C. Kimber, A. Whitley, A. S. Doney, M. I. McCarthy, A. T. Hattersley, A. D. Morris and C. N. Palmer, Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study,(2007) 2178-2182; DOI: 10.2337/db07-0440.
    Open DOISearch in Google Scholar
  63. J. K. Wolford, K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan and R. M. Watanabe, Sequence variation inmay underlie differential response to troglitazone,(2005) 3319-3325; DOI: 10.2337/diabetes.54.11.3319.
    Open DOISearch in Google Scholar
  64. S. Snitker, R. M. Watanabe, I. Ani, A. H. Xiang, A. Marroquin, C. Ochoa, J. Goico, A. R. Shuldiner and T. A. Buchanan, Troglitazone in prevention of diabetes (TRIPOD) study, Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala PPAR-γ-2 gene variant: results from the troglitazone in prevention of diabetes (TRIPOD) study,(2004) 1365-1368; DOI: 10.2337/diacare.27.6.1365.
    Open DOISearch in Google Scholar
  65. M. Blüher, G. Lübben and R. Paschke, Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes,(2003) 825-831; DOI: 10.2337/diacare.26.3.825.
    Open DOISearch in Google Scholar
  66. K. H. Zhang, Q. Huang, X. P. Dai, J. Y. Yin, W. Zhang, G. Zhou, H. H. Zhou and Z. Q. Liu, Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus,(2010) 1022-1030; DOI: 10.1177/0091270009355159.
    Open DOISearch in Google Scholar
  67. H. J. Pan, P. Reifsnyder, D. E. Vance, Q. Xiao and E. H. Leiter, Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes,(2005) 1854-1862; DOI: 10.2337/diabetes.54.6.1854.
    Open DOISearch in Google Scholar
  68. R. L. Jacobs, C. Devlin, I. Tabas and D. E. Vance, Targeted deletion of hepatic CTP: phosphocholine cytidyltransferase a in mice decreases plasma high density and very low density lipoproteins,(2004) 47402-47410; DOI: 10.1074/jbc.M404027200.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10007-010-0040-9 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English, Croatian, Slovenian
Page range: 387 - 406
Published on: Dec 17, 2010
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
pharmacogenetics,
oral antidiabetics
Related subjects:
Pharmacy,
Pharmacy, other

© 2010 Una Glamočlija, Adlija Jevrić-Čaušević, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.

Volume 60 (2010): Issue 4 (December 2010)
Previous article
Next article